Nao Medical has not opened Awiqli-specific appointments. Patients can book general diabetes medication management while the team confirms product availability, pharmacy ordering, insurance access, and the clinic workflow.
Diabetes care | New York
Awiqli is the brand name for insulin icodec-abae, a concentrated U-700 basal insulin approved in March 2026 for adults with type 2 diabetes. It is injected once weekly. Novo Nordisk has said it expects a nationwide U.S. launch in the second half of 2026. Nao Medical has not confirmed product availability or an Awiqli-specific workflow, so the information here is educational and does not activate medication-specific booking.
Awiqli is FDA approved, and Novo Nordisk has announced an expected nationwide U.S. launch in the second half of 2026. Nao Medical has not confirmed product availability, insurance access, or a medication-specific workflow. General diabetes medication-management visits remain available.
Awiqli is indicated with diet and exercise to improve glycemic control in adults with type 2 diabetes. It is not labeled for children, type 1 diabetes, diabetic ketoacidosis, or casual substitution for a daily basal insulin.
A future protocol would need to confirm adult type 2 diabetes, current insulin exposure, glucose-monitoring capacity, and hypoglycemia awareness. It would also cover kidney and liver context, concurrent medicines, adherence, visual or dexterity limitations, and the ability to follow one fixed weekly dosing day.
Awiqli is a U-700 insulin given under the skin once weekly on the same day each week. Its pen delivers weekly doses in 10-unit increments. Starting and conversion instructions are product-specific and must not be inferred by multiplying doses without the full label and prescriber oversight.
The label calls for individualized dosing, close glucose monitoring when changing insulin regimens, and increased monitoring during regimen changes. Because the effect is prolonged, a dosing mistake can create prolonged hypoglycemia risk.
A brand name is not enough to determine whether treatment is appropriate. The clinician must connect the label to the patient's diagnoses, current medicines, prior treatment, laboratory results, preferences, and coverage.
A future protocol would need to confirm adult type 2 diabetes, current insulin exposure, glucose-monitoring capacity, and hypoglycemia awareness. It would also cover kidney and liver context, concurrent medicines, adherence, visual or dexterity limitations, and the ability to follow one fixed weekly dosing day.
The label calls for individualized dosing, close glucose monitoring when changing insulin regimens, and increased monitoring during regimen changes. Because the effect is prolonged, a dosing mistake can create prolonged hypoglycemia risk.
Keep the Awiqli-specific workflow inactive until pharmacy and payer access, adult type 2 diabetes scope, U-700 competency, conversion and titration protocol, glucose monitoring, rescue planning, and escalation coverage are documented.
Concentrated once-weekly insulin creates a high-consequence dosing-error risk. Do not use this information as a conversion table or self-start guide. A safe service needs controlled prescribing, education, medication reconciliation, glucose monitoring, hypoglycemia rescue planning, and rapid access to clinical support.
An evaluation may lead to another medicine, more testing, a referral, or no medication change.
The health plan and dispensing pharmacy make coverage and fulfillment decisions. Prior authorization may be required.
The clinic cards below show places to start an evaluation. They do not prove that a product is stocked, dispensed, taught, or administered at that site.
The sequence protects safety and keeps a product request from bypassing diagnosis, records, monitoring, access, or referral needs.
Patients who need medication review should use the established diabetes or primary-care pathway rather than wait for Awiqli.
Nao Medical must document orderability, pharmacy fulfillment, package availability, coverage, and patient-support resources before opening medication-specific appointments.
A named clinician must approve candidacy, conversion, titration, missed-dose, monitoring, rescue, and escalation workflows.
Training must verify the weekly schedule, U-700 concentration, exact pen use, glucose monitoring, hypoglycemia response, and medication-list accuracy before treatment.
Choose a nearby Nao Medical clinic as a starting point for evaluation or care coordination.
Capability boundary: these location cards do not establish that a medicine, device, laboratory test, injection, or specialty workflow is available at every site. Confirm the exact service before travel.
Bronx
932 E 174th St, Bronx, NY 10460
A place to begin evaluation and care coordination near West Farms, Crotona Park East, and nearby Bronx neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
37-15 23rd Ave, Astoria, NY 11105
A place to begin evaluation and care coordination near Astoria, Ditmars, East Elmhurst, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Bronx
2063A Bartow Ave, Bronx, NY 10475
A place to begin evaluation and care coordination near Co-op City, Pelham Bay, Baychester, and nearby Bronx neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Brooklyn
341 Eastern Pkwy, Brooklyn, NY 11216
A place to begin evaluation and care coordination near Crown Heights, Prospect Heights, and nearby Brooklyn neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Long Island
232 W Old Country Rd, Hicksville, NY 11801
A place to begin evaluation and care coordination near Hicksville, Plainview, Bethpage, and nearby Nassau County communities. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
80-10 Northern Blvd, Jackson Heights, NY 11372
A place to begin evaluation and care coordination near Jackson Heights, Elmhurst, Corona, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
90-18 Sutphin Blvd, Jamaica, NY 11435
A place to begin evaluation and care coordination near Jamaica, Briarwood, Richmond Hill, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
30-07 36th Ave, Astoria, NY 11106
A place to begin evaluation and care coordination near Long Island City, Astoria, Sunnyside, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Long Island
135 Mineola Blvd, Mineola, NY 11501
A place to begin evaluation and care coordination near Mineola, Garden City, Westbury, and nearby Nassau County communities. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Manhattan
259 1st Ave, New York, NY 10003
A place to begin evaluation and care coordination near StuyTown, the East Village, Gramercy, and nearby Manhattan neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Brooklyn
308 Graham Ave, Brooklyn, NY 11211
A place to begin evaluation and care coordination near Williamsburg, Greenpoint, Bushwick, and nearby Brooklyn neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Compare focused options, prepare for an evaluation, and connect medication questions with broader care.
Use the broader diabetes pathway for treatment needs that cannot wait.
Use ongoing primary care to connect medication decisions with the rest of your health history.
Explore Nao Medical's broader weight-management program and treatment options.
Keep adult weight-treatment questions separate from weekly insulin.
Connect diabetes treatment with cardiovascular risk care.
Answers reflect current official sources and Nao Medical's limited evaluation and coordination scope.
These sources support product identity, approval, current labeling, availability, and clinical boundaries. They do not prove Nao Medical site capability or health-plan coverage.
FDA-approved identity, adult type 2 diabetes indication, U-700 concentration, weekly dosing, conversion, and safety information.
Open official sourceManufacturer product information and launch resources. Nao-specific availability and workflow remain separate checks.
Open official sourcePerson-centered insulin selection, monitoring, hypoglycemia prevention, and reassessment.
Open official sourceSource and label check completed August 1, 2026. Named clinical and operations review is still pending.
The FDA approved Awiqli (insulin icodec-abae) on March 26, 2026 for adults with type 2 diabetes. It is a U-700 once-weekly basal insulin. Novo Nordisk has said it expects a nationwide U.S. launch in the second half of 2026, but Nao Medical has not confirmed product availability, insurance access, or an Awiqli-specific prescribing workflow.
Patients can learn about the product and prepare questions. Published information does not mean Awiqli is stocked, prescribed, dispensed, or operational at Nao Medical.
Patients can book diabetes medication management for current treatment, monitoring, and a review of approved and available options.
Awiqli is not a simple one-for-one swap from daily insulin. Product concentration, weekly dosing, glucose monitoring, and prolonged hypoglycemia risk require close medical supervision.
Official references: FDA prescribing information and manufacturer prescribing information.
General information only. The information here is not medical advice and does not replace diagnosis, treatment, or guidance from a licensed clinician.
Content was updated August 2, 2026 from the cited sources and Nao Medical's current service information. Medical guidance, prescribing information, medication availability, and insurance rules can change. A licensed clinician must confirm current information and determine each patient's eligibility, testing, treatment, administration setting, and follow-up. Call 911 for a medical emergency. Contact Nao Medical with a question or correction.
(917) 310-3371